Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations
Dupilumab, the first biologic treatment approved for moderate to severe atopic dermatitis, has completely revolutionized the management of such disease allowing long-term control of its clinical signs and symptoms. Nevertheless, data regarding the safety and effectiveness profile of dupilumab in patients belonging to special populations are scarce. This observational, multicentric study analysed the effectiveness and safety profile of dupilumab over 3 years in the treatment of 70 patients with moderate to severe atopic dermatitis and associated comorbidities such as cancers, renal and liver failure, viral chronic infections, and degenerative and autoimmune neurological disorders. Patients achieved a significant improvement in both physician-assessed and patient-reported outcomes after 16 weeks of treatment, with a continuous therapeutic response maintained throughout the 156-week period. The safety profile was comparable to clinical trials and real-world data involving patients without significant comorbidities. In conclusion, the findings support the safety of dupilumab in managing severe atopic dermatitis in fragile patients.
Authors
- Giovanni Pellacani (ORCID: https://orcid.org/0000-0002-7222-2951)
- Martina Maurelli (ORCID: https://orcid.org/0000-0001-7492-8010)
- Vincenzo Panasiti (ORCID: https://orcid.org/0000-0003-1589-867X)
- Simone Ribero (ORCID: https://orcid.org/0000-0002-0098-1406)
- Ester Del Duca (ORCID: https://orcid.org/0000-0001-7948-8536)
- Niccolò Gori (ORCID: https://orcid.org/0000-0003-1987-0623)
- Claudia Paganini
- Alvise Sernicola (ORCID: https://orcid.org/0000-0002-1985-0326)
- Marco Galluzzo (ORCID: https://orcid.org/0000-0002-3424-5175)
- Maria Mariano (ORCID: https://orcid.org/0000-0002-7964-3388)
- Maria Concetta Fargnoli (ORCID: https://orcid.org/0000-0002-7249-2556)
- Luigi Bianchi (ORCID: https://orcid.org/0000-0001-8724-9092)
- Michela Ortoncelli (ORCID: https://orcid.org/0009-0002-6774-7080)
- Gaia Moretta (ORCID: https://orcid.org/0000-0002-8839-5961)
- Ketty Peris (ORCID: https://orcid.org/0000-0002-5237-0463)
- Sabatino Pallotta (ORCID: https://orcid.org/0000-0003-4827-2892)
- Rosa Coppola
- Ersilia Tolino (ORCID: https://orcid.org/0000-0001-7861-9338)
- Giampiero Girolomoni
- Elena Ippoliti (ORCID: https://orcid.org/0009-0009-6455-0531)
- Luisa Boeti (ORCID: https://orcid.org/0009-0001-1290-0474)
Institutions
- Università Cattolica del Sacro Cuore (IT)
- University of Rome Tor Vergata (IT)
- University of Verona (IT)
- University of Padua (IT)
- Agostino Gemelli University Polyclinic (IT)
- Istituto Dermopatico dell'Immacolata (IT)
- Policlinico Tor Vergata (IT)
- San Gallicano Hospital (IT)
- Campus Bio Medico University Hospital (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- University of Turin (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Acta Dermato Venereologica
- Published
- 2025-10-02
- DOI
- https://doi.org/10.2340/actadv.v105.43523
- Citations
- 3
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 6.01
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Sanofi
- Regeneron Pharmaceuticals
- Les Laboratories Pierre Fabre
- Incyte
- Galderma
- Sun Pharma
- LEO Pharma
- Samsung